CriticalSorb Delivery Technology Shows Excellent Local Tolerability in Long Term Preclinical Studies

CriticalSorb Delivery Technology Shows Excellent Local Tolerability in Long Term Preclinical Studies
8th March 2011,Nottingham, UK

Critical Pharmaceuticals today announces the results of a long-term preclinical study that confirms the excellent local tolerability of its unique and proprietary CriticalSorbTM nasal drug delivery technology. The emerging biotechnology company is now preparing to take the technology forward into a phase I clinical trial.

CriticalSorbTM is already used in a number of marketed drugs for intravenous and oral administration and the results of this study complete the toxicology package for the nasal route of administration.

CriticalSorbTM is a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs. Biological drugs represent a $90 billion market, and yet nearly all need to be administered by frequent injection. CriticalSorbTM has the potential to transform the delivery of biological drugs by enabling non-invasive delivery that would be strongly preferred by patients. 

Critical Pharmaceuticals is developing the CriticalSorbTM nasal delivery technology with support from a Wellcome Trust Translation Award. The first product to be developed using the technology is a nasal formulation of human growth hormone (CP024).

The toxicological study with CriticalSorbTM was designed to investigate the effects of repeated intranasal administration over a period of six months. No adverse responses were identified in clinical observations, bodyweight, food or water consumption, ophthalmoscopy, haematology, blood chemistry, urinalysis or necropsy. In addition, histopathology examination revealed no adverse health effect at any dose and a ‘No Observed Adverse Effect Level' (NOAEL) was therefore considered to be the highest dose tested. In addition to the six month study on CriticalSorbTM and in preparation for an upcoming Phase 1 clinical trial, Critical Pharmaceuticals has also completed a chronic study with repeated intranasal administration of CP024 over a period of 14 days that also shows excellent tolerability with no adverse effects reported.

Professor Lisbeth Illum, Chief Executive Officer of Critical Pharmaceuticals is enthusiastic about the excellent tolerability results with CriticalSorb "We have already demonstrated that CriticalSorbTM can achieve exceptional bioavailabilities for drugs that are difficult to deliver and these latest results confirm that CriticalSorbTM is well tolerated and doesn't damage the nasal mucosa, something that has been a significant issue for other nasal delivery systems. We look forward to confirming these excellent results in clinical studies and to address the significant need for improved biotechnology products that provide an attractive alternative to frequent injection for patients, clinicians and healthcare providers." 

About Critical Pharmaceuticals

Critical Pharmaceuticals is a Nottingham UK-based biotechnology company developing a pipeline of unique biological drug products utilizing its proprietary drug delivery technologies. These technologies enable the development of sustained release injectable depot and nasal delivery of proteins and peptides and small molecular weight drugs. As well as developing it's own pipeline, Critical Pharmaceuticals works in partnership with other pharmaceutical and biotechnology companies to enhance the delivery of their novel drug products. For more information visit www.criticalpharmaceuticals.com.

About the Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk 

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.